Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
76 hedge funds and large institutions have $31.4M invested in Merrimack Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 20 closing their positions.
363% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $352K
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
6% less funds holding
Funds holding: 81 → 76 (-5)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
49% less capital invested
Capital invested by funds: $61.4M → $31.4M (-$30M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.37M |
| 2 |
NM
Newtyn Management
New York
|
+$4.16M |
| 3 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$1.1M |
| 4 |
Goldman Sachs
New York
|
+$906K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$844K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 2 |
BlackRock
New York
|
-$4.66M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.98M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.01M |
| 5 |
Renaissance Technologies
New York
|
-$1.87M |
MACK Hedge Fund Activity: Q2 2018 in Review
76 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2018, worth a combined $31.4M — down 49% from $61.4M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MACK and 17 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 21 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $9.37M. The largest seller was Fidelity Investments, cutting an estimated $13.2M.
- 76 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2018, down from 81 in Q1 2018.
- Funds reported $31.4M of Merrimack Pharmaceuticals, Inc. stock for Q2 2018, down 49% quarter-over-quarter.
- 17 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2018 and 20 closed out, a net change of -3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2018 was BVF Inc, an estimated $9.37M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2018 was Fidelity Investments, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2018.